May 17th 2024
Imdelltra (tarlatamab-dlle) is the first T-cell engager therapy approved for extensive stage small cell lung cancer.
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
March 8th 2022Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.